Form 8-K - Current report:
SEC Accession No. 0001193125-26-232717
Filing Date
2026-05-20
Accepted
2026-05-20 16:35:15
Documents
11
Period of Report
2026-05-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pvla-20260520.htm   iXBRL 8-K 50008
2 PRESS RELEASE ISSUED BY PALVELLA THERAPEUTICS, INC. ON MAY 20, 2026 pvla-ex99_1.htm EX-99.1 47232
3 GRAPHIC img6060170_0.jpg GRAPHIC 34152
  Complete submission text file 0001193125-26-232717.txt   259209

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pvla-20260520.xsd EX-101.SCH 26040
14 EXTRACTED XBRL INSTANCE DOCUMENT pvla-20260520_htm.xml XML 4710
Mailing Address 353 W. LANCASTER AVENUE SUITE 200 WAYNE PA 19087
Business Address 353 W. LANCASTER AVENUE SUITE 200 WAYNE PA 19087 (484) 253-1461
PALVELLA THERAPEUTICS, INC. (Filer) CIK: 0001583648 (see all company filings)

EIN.: 300784346 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37471 | Film No.: 261004568
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)